Hela Romdhani
Montreal
Education
Ph.D., mathematics and statistics, Laval University; M.S., information processing, National Engineering School of Tunis; B.S., statistics and data analysis, Higher School of Statistics and Data Analysis; Diploma, mathematics and computer sciences, Higher School Preparatory Classes
Summary of Experience
Dr. Romdhani specializes in the application of advanced statistical methods to address a wide array of research questions in health care, including in the area of health economics and outcomes research (HEOR). She has broad quantitative research experience conducting studies to assess the economic burden of various illnesses, treatment patterns, and drug safety and efficacy profiles in a range of therapeutic areas, including oncology, gastroenterology, immunology, neurology, cardiology, infectious diseases, and rare and hereditary diseases. Dr. Romdhani’s expertise includes conducting real-world evidence (RWE) studies, retrospective database analyses, chart review studies, and systematic and targeted literature reviews. Her research has been published in peer-reviewed journals and presented at clinical and economic research conferences.
Selected Publishing
-
Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study
Drugs - Real World Outcomes, 2021
2021Gordan L, Chang M, Lafeuille MH, Romdhani H, Paramasivam F, Maiese EM, McKay C
-
Disease Management and Outcomes in Patients Hospitalized for Acute Heart Failure in Japan
Cardiology and Therapy, 2021
2021Chen L, Ionescu-Ittu R, Romdhani H, Guérin A, Kessler P, Borentain M, Friend K, DeSouza M, Sato N
-
Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
PharmacoEconomics - Open, 2019
2019Emond B, Joshi K, El Khoury AC, Lafeuille MH, Pilon D, Tandon N, Romdhani H, Lefebvre P
-
Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy
Clinical Lymphoma, Myeloma & Leukemia, 2019
2019Emond B, Sundaram M, Romdhani H, Lefebvre P, Wang S, Mato A
-
Long-Term Benefits of Rapid Antiretroviral Therapy Initiation in Reducing Medical and Overall Health Care Costs Among Medicaid-Covered Patients with Human Immunodeficiency Virus
Journal of Managed Care & Specialty Pharmacy, 2019
2019Benson C, Emond B, Romdhani H, Lefebvre P, Côté-Sergent A, Shohoudi A, Tandon N, Chow W, Dunn K
-
Economic burden of treatment failure in chronic lymphocytic leukemia patients
Current Medical Research and Opinion. 2018 Jun;34(6):1135-1142
2018Wang S, Lafeuille MH, Lefebvre P, Romdhani H, Emond B, Senbetta M
-
Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV
Journal of Managed Care & Specialty Pharmacy. 2018 Oct;24(10):1040-1051
2018Dunn K, Lafeuille MH, Jiao X, Romdhani H, Emond B, Woodruff K, Pesa J, Tandon N, Lefebvre P
-
Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer
Advances in Therapy. 2018 Aug;35(8):1251-1264
2018Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA
-
Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
Advances in Therapy. 26 Mar 2018:1-12
2018Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, Guerin A, Gauthier G, Wu EQ, Niravath P, Small T